Investors: Overview

We are committed to solving some of the toughest challenges in highly resistant cancers and viruses. Through extensive relationships with world-renowned research organizations, we aim to develop better treatments that can make a real impact in people’s lives.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of soft tissue sarcoma (STS) lung metastases and relapsed or refractory acute myeloid leukemia (AML).

Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma.

Stock Information

Latest News

Latest Quarterly

Latest Filings

Corporate Presentation

Investor Relations

JTC Team, LLC.
Jenene Thomas
T: 833-475-8247


Grant Thornton LLP

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436

Legal Counsel

ArentFox Schiff LLP